Product Details
| Product Name:
MOMIPP |
CAS No.:
1363421-46-8 |
| Purity:
99.66% |
Supply Ability:
10g |
| Release date:
2025/07/16 |
Product Introduction
Bioactivity
| Name | MOMIPP |
| Description | MOMIPP is a PIKfyve inhibitor and a macropinocytosis inducer. MOMIPP readily penetrates the blood-brain barrier and is moderately effective in suppressing progression of intracerebral glioblastoma xenografts[1][2]. |
| Cell Research | When JNK activation (phosphorylation) was assessed by western blot analysis after 24 h, MOMIPP(10 μM)has been found that induced major increases in JNK1/2 phosphorylation[2]. |
| Animal Research | MOMIPP (Athymic CrTac:NCR-Foxn1 mice (female, 7-8 weeks); 80 mg/kg; i.p.; once daily; for 15 consecutive days) suppressed progression of intracerebral glioblastoma xenografts[2]. |
| In vitro | MOMIPP can induce intense macropinocytosis, leading to methuosis in cultured glioblastoma cells at low micromolar concentrations[1]. MOMIPP(3 μM) induces cell vacuolization in U373 and Hs683 cell lines[1]. The cytotoxic IPP compound, MOMIPP, causes early disruptions of glucose uptake and glycolytic metabolism. Coincident with these metabolic changes, MOMIPP selectively activates the JNK1/2 stress kinase pathway, resulting in phosphorylation of c-Jun, Bcl-2 and Bcl-xL[2]. |
| In vivo | MOMIPP (80 mg/kg; i.p.; once daily; for 15 consecutive days) shows result that MOMIPP is moderately effective in suppressing progression of intracerebral glioblastoma xenografts. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 15.13 mg/mL (51.76 mM), Sonication is recommended.
|
| Keywords | PIKfyve | MOMIPP | Macropinocytosis | JNK1/2 | Inhibitor | inhibit | Fab1 | c-Jun | Bcl-xL | Bcl-2 | BBB |
| Inhibitors Related | Myricetin | Erucic acid | Sapanisertib | (2S,3R,4S)-4-Hydroxyisoleucine | 3-Methyladenine | Duvelisib (R enantiomer) hydrochloride | Isoprenaline hydrochloride | Quercetin | Inavolisib | Quercetin Dihydrate | Apilimod | Idelalisib |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Neural Regeneration Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | NO PAINS Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1276186-19-6
$293.00 / 1mg
-
CAS:1241390-29-3
$38.00 / 2mg
-
CAS:4393-06-0
$30.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States